Sylvester, Syapse to launch precision medicine initiative

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Sylvester Comprehensive Cancer Center, part of UHealth–the University of Miami Health System, and Syapse, a precision oncology company, announced that they will team up to launch a new precision medicine initiative at Sylvester.

By partnering with Syapse, Sylvester physicians will be able to more efficiently deliver personalized care that matches patients with targeted, cutting-edge therapies based on the clinical and molecular profile of the patient, leading to improved survival rates and better health outcomes.

Through the partnership with Syapse, Sylvester physicians will now have a robust platform that brings together clinical, molecular, treatment, and outcomes data to power this new era of precision medicine clinical workflows.

The Syapse platform will provide access to the largest, real-world precision oncology data sharing consortium in the world, enabling oncologists to make better decisions for their patients using real-world treatment and outcomes data on clinically and molecularly similar patients.

The Syapse platform is adopted by Intermountain Healthcare, Providence St. Joseph’s Health, Stanford Healthcare, Henry Ford Health System, Catholic Health Initiatives and Dignity Health.

YOU MAY BE INTERESTED IN

George F. Tidmarsh has resigned from his job as director of the FDA Center for Drug Evaluation and Research in the aftermath of a lawsuit by a former associate and a probe into what an HHS spokesperson described as “serious concerns about his personal conduct.”
Research has shown that delivering tumor profiling results to cancer patients prior to initiation of treatment and connecting patients harboring an actionable oncogenic mutation with the right targeted therapy can deliver superior patient outcomes. To fulfill this promise of precision medicine, we need to ensure more targeted therapies are available to patients who need them. Fortunately, this work is well underway. xxx:more

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login